Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Assessment of 4D 18F-FDG PET-CT in Radiotherapy for Non Small Cell Lung Cancers

NCT: NCT01421953 · COMPLETED

NCT IDNCT01421953
StatusCOMPLETED
Start Date2011-08
Completion2012-11

Brief Summary

Computed tomography (CT) images, used for radiotherapy planning, are often caught out in lung target volumes delineation because of their inability to differentiate between neoplasia, inflammation and atelectasia. Positron Emission Tomography (PET) is a new functional imaging modality and is currently used in the diagnosis and the staging of lung cancers. The aim of this study is to evaluate the impact of 4D 18F-FDG-PET-CT on radiotherapy planning for lung cancers.

Frequently Asked Questions

What is Assessment of 4D 18F-FDG PET-CT in Radiotherapy for Non Small Cell Lung Cancers?

Assessment of 4D 18F-FDG PET-CT in Radiotherapy for Non Small Cell Lung Cancers is a clinical trial registered under NCT01421953. Current status: COMPLETED.

What is the status of NCT01421953?

The current status of NCT01421953 (Assessment of 4D 18F-FDG PET-CT in Radiotherapy for Non Small Cell Lung Cancers) is: COMPLETED.

When did Assessment of 4D 18F-FDG PET-CT in Radiotherapy for Non Small Cell Lung Cancers start?

Assessment of 4D 18F-FDG PET-CT in Radiotherapy for Non Small Cell Lung Cancers started on 2011-08.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑